Haploidentical hematopoietic cell transplant recipient presents with late-onset Epstein Barr virus-associated posttransplant lymphoproliferative disorder.
Adam Phillip Gordon BraunLawrence LiuMonzr M Al MalkiPamela S BeckerPublished in: EJHaem (2023)
Posttransplant lymphoproliferative disease (PTLD) is a potentially life-threatening complication of hematopoietic cell transplantation. With improvements in Epstein-Barr virus (EBV) monitoring and supportive care, PTLD incidence has decreased throughout the history of bone marrow transplantation. It is rare to develop PTLD after the first year following transplant, across all donor categories. In this case, we hope to elucidate details that may have predisposed to this unusual presentation. We present the case of a 55-year-old gentleman with acute myeloid leukemia who underwent a haploidentical transplant for consolidation and presented with fatigue, lethargy and presumed septic shock nearly 7 years after transplant.
Keyphrases
- epstein barr virus
- bone marrow
- late onset
- diffuse large b cell lymphoma
- acute myeloid leukemia
- septic shock
- stem cell transplantation
- healthcare
- mesenchymal stem cells
- early onset
- peripheral blood
- risk factors
- low dose
- physical activity
- chronic pain
- allogeneic hematopoietic stem cell transplantation
- pain management